Treatment beyond progression
Participants will be permitted to continue treatment beyond initial progression if they meet the following criteria:Investigator-assessed clinical benefitTolerance of study drugStable performance statusParticipants on Arm B (extended interval ICI) who experience progression and are clinically fit to continue treatment may continue the extended interval dosing or will have the option to intensify their treatment (i.e., cross over back to Arm A regimen). ICI treatment should be discontinued permanently upon documentation of further progression.